{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:03:54Z","timestamp":1785783834665,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Anti-Cancer Association Clinical Research","award":["No. XH2023 5008"],"award-info":[{"award-number":["No. XH2023 5008"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81670188"],"award-info":[{"award-number":["No. 81670188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2019YJ0028"],"award-info":[{"award-number":["No. 2019YJ0028"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06223-9","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T15:33:49Z","timestamp":1747582429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A comprehensive analysis of bone marrow-derived cytogenetic abnormalities in multiple myeloma patients with extramedullary disease"],"prefix":"10.1007","volume":"151","author":[{"given":"Juan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5389-7550","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5855-4343","authenticated-orcid":false,"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"7","key":"6223_CR1","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R et al (2022) Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res 12(7):2950\u20132965","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6223_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","volume":"97","author":"L Besse","year":"2016","unstructured":"Besse L, Sedlarikova L, Greslikova H et al (2016) Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 97(1):93\u2013100","journal-title":"Eur J Haematol"},{"issue":"1","key":"6223_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ (2020) Extramedullary multiple myeloma. Leukemia 34(1):1\u201320","journal-title":"Leukemia"},{"issue":"28","key":"6223_CR4","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blade","year":"2011","unstructured":"Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R (2011) Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29(28):3805\u20133812","journal-title":"J Clin Oncol"},{"key":"6223_CR5","doi-asserted-by":"publisher","first-page":"1084683","DOI":"10.3389\/fonc.2022.1084683","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Han X, Zheng G et al (2022) The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: a retrospective single-center study in China. Front Oncol 12:1084683","journal-title":"Front Oncol"},{"key":"6223_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN (2024) Chromosomal defects in multiple myeloma. Blood Rev 64:101168","journal-title":"Blood Rev"},{"issue":"12","key":"6223_CR7","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","volume":"18","author":"LJ Costa","year":"2020","unstructured":"Costa LJ, Usmani SZ (2020) Defining and managing high-risk multiple myeloma: current concepts. J Natl Compr Canc Netw 18(12):1730\u20131737","journal-title":"J Natl Compr Canc Netw"},{"key":"6223_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934008","volume":"12","author":"MD Diamantidis","year":"2022","unstructured":"Diamantidis MD, Papadaki S, Hatjiharissi E (2022) Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. Front Oncol 12:934008","journal-title":"Front Oncol"},{"issue":"10","key":"6223_CR9","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Blood EA, Oken MM et al (2002) Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99(10):3735\u20133741","journal-title":"Blood"},{"issue":"2","key":"6223_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ejh.13981","volume":"111","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Eikema DJ, Koster L et al (2023) Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study. Eur J Haematol 111(2):181\u2013190","journal-title":"Eur J Haematol"},{"issue":"14","key":"6223_CR11","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M et al (2024) Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol 42(14):1665\u20131675","journal-title":"J Clin Oncol"},{"key":"6223_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05588-6","author":"S Gao","year":"2024","unstructured":"Gao S, Dong F, Yang P et al (2024) 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-023-05588-6","journal-title":"Ann Hematol"},{"issue":"7","key":"6223_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00277-022-04856-1","volume":"101","author":"P Hagen","year":"2022","unstructured":"Hagen P, Sellin M, Berg S, Zhang J (2022) Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. Ann Hematol 101(7):1407\u20131420","journal-title":"Ann Hematol"},{"issue":"5","key":"6223_CR14","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC et al (2024) Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica 109(5):1514\u20131524","journal-title":"Haematologica"},{"key":"6223_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00568-3","author":"MH Jagosky","year":"2020","unstructured":"Jagosky MH, Usmani SZ (2020) Extramedullary disease in multiple myeloma. Curr Hematol Malig Rep. https:\/\/doi.org\/10.1007\/s11899-020-00568-3","journal-title":"Curr Hematol Malig Rep"},{"key":"6223_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02206-w","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T et al (2024) Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. https:\/\/doi.org\/10.1038\/s41375-024-02206-w","journal-title":"Leukemia"},{"issue":"9","key":"6223_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","volume":"12","author":"R Jim\u00e9nez-Segura","year":"2022","unstructured":"Jim\u00e9nez-Segura R, Rosi\u00f1ol L, Cibeira MT et al (2022) Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J 12(9):135","journal-title":"Blood Cancer J"},{"key":"6223_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245829","author":"M Kleber","year":"2023","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E (2023) The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15245829","journal-title":"Cancers (Basel)."},{"issue":"11","key":"6223_CR19","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","volume":"24","author":"X Li","year":"2019","unstructured":"Li X, Chen W, Wu Y et al (2019) 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China. Oncologist 24(11):e1132\u2013e1140","journal-title":"Oncologist"},{"issue":"1","key":"6223_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W et al (2024) Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia 38(1):149\u2013159","journal-title":"Leukemia"},{"key":"6223_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19340","author":"R Liu","year":"2024","unstructured":"Liu R, Yang R, Xu X et al (2024) Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.19340","journal-title":"Br J Haematol"},{"issue":"12","key":"6223_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/ajh.25994","volume":"95","author":"M Locher","year":"2020","unstructured":"Locher M, Steurer M, Jukic E et al (2020) The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. Am J Hematol 95(12):1562\u20131571","journal-title":"Am J Hematol"},{"issue":"2","key":"6223_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM (2017) Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14(2):100\u2013113","journal-title":"Nat Rev Clin Oncol"},{"key":"6223_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411259","author":"R McAvera","year":"2023","unstructured":"McAvera R, Quinn J, Murphy P, Glavey S (2023) Genetic abnormalities in extramedullary multiple myeloma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241411259","journal-title":"Int J Mol Sci"},{"key":"6223_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100643","volume":"41","author":"A Paner","year":"2020","unstructured":"Paner A, Patel P, Dhakal B (2020) The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev 41:100643","journal-title":"Blood Rev"},{"issue":"1","key":"6223_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","volume":"14","author":"O Pasvolsky","year":"2024","unstructured":"Pasvolsky O, Ghanem S, Milton DR et al (2024) Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14(1):4","journal-title":"Blood Cancer J"},{"issue":"9","key":"6223_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Morgan GJ (2017) Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 17(9):543\u2013556","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6223_CR28","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99(2):360\u2013364","journal-title":"Haematologica"},{"key":"6223_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27327","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Kumar S (2024) High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27327","journal-title":"Am J Hematol"},{"key":"6223_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F (2024) Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ Book. https:\/\/doi.org\/10.1200\/EDBK_433520","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"6223_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B et al (2024) Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38(2):365\u2013371","journal-title":"Leukemia"},{"issue":"3","key":"6223_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E et al (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 194(3):496\u2013507","journal-title":"Br J Haematol"},{"issue":"4","key":"6223_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ (2021) Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J 11(4):83","journal-title":"Blood Cancer J"},{"issue":"8","key":"6223_CR34","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971\u2013976","journal-title":"Blood"},{"issue":"11","key":"6223_CR35","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761\u20131767","journal-title":"Haematologica"},{"issue":"7","key":"6223_CR36","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cncr.34641","volume":"129","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xu J, Xu B et al (2023) The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: The faster, the worse. Cancer 129(7):1005\u20131016","journal-title":"Cancer"},{"issue":"6","key":"6223_CR37","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/10428194.2012.740562","volume":"54","author":"M Weinstock","year":"2013","unstructured":"Weinstock M, Ghobrial IM (2013) Extramedullary multiple myeloma. Leuk Lymphoma 54(6):1135\u20131141","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6223_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH et al (2024) Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol 17(1):23","journal-title":"J Hematol Oncol"},{"key":"6223_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938392","volume":"12","author":"H You","year":"2022","unstructured":"You H, Jin S, Wu C et al (2022) The independent adverse prognostic significance of 1q21 gain\/amplification in newly diagnosed multiple myeloma patients. Front Oncol 12:938392","journal-title":"Front Oncol"},{"issue":"10","key":"6223_CR40","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y et al (2023) Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol 98(10):1540\u20131549","journal-title":"Am J Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06223-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T06:32:38Z","timestamp":1749537158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06223-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["6223"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06223-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6188588\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethical Review Committee of West China Hospital, Sichuan University. All methods used in this study follow the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"169"}}